Products for Research Use Only

VBY-825

CAT: 0804-HY-15958-01Size: 1 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-15958-01Size:1 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
VBY-825 is an orally available novel reversible cathepsin inhibitor that has high inhibitory potency against cathepsin B, L, S and V, and possesses anti-tumor, anti-inflammatory and analgesic effects[1][2][3].
CAS Number
1310340-58-9
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Cathepsin
Type
Reference compound
Related Pathways
Metabolic Enzyme/Protease
Applications
Cancer-Kinase/protease
Field of Research
Cancer; Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/VBY-825.html
Purity
99.81
Solubility
DMSO : 125 mg/mL (ultrasonic)
Smiles
CC[C@H](NC([C@@H](N[C@@H](C1=CC=C(F)C=C1)C(F)(F)F)CS(=O)(CC2CC2)=O)=O)C(C(NC3CC3)=O)=O
Molecular Formula
C23H29F4N3O5S
Molecular Weight
535.55
Precautions
H302, H315, H319, H335
References & Citations
[1]Elie BT, et al. Identification and pre-clinical testing of a reversible cathepsin protease inhibitor reveals anti-tumor efficacy in a pancreatic cancer model. Biochimie. 2010 Nov;92 (11) :1618-24.|[2]Umaretiya, et al. Cathepsin Inhibitor, VBY-825, Attenuates Bone Cancer Induced Pain in Mice. The University of Arizona. |[3]Laura Orellano, et al. Therapeutic potential of VBY-825 in MSU crystal-induced NLRP3 inflammasome activation. The Journal of Immunology. 2024. 212 (1_Supplement) : 0957_5533.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
Cathepsin K; Cathepsin S

Popular Products